Navigating the Road to Recovery in Depression: Pit Stops, Pot Holes, Detours, and Ultimate Recovery: Addressing Barriers to Achieving Recovery in Major Depression

Navigating the Road to Recovery in Depression: Pit Stops, Pot Holes, Detours, and Ultimate Recovery: Addressing Barriers to Achieving Recovery in Major Depression - Pre-Activity Survey

CME/CE Information
References

Activity Progress
Pre-Activity Survey
Page 1
Post-Activity Survey
CME Evaluation/Print Certificate

What percentage of patients discontinue their medication by 3 months of treatment?* 13%
28%
44%
79%
What would be the best next step in managing this patient’s MDD?
• 47-year-old male, office manager, BMI 31, no other health conditions
• Initial PHQ-9 score of 15
• Started on SSRI 2 weeks prior, as he preferred pharmacotherapy over psychotherapy
• Current PHQ-9 score of 13* Switch therapy to another SSRI
Add an atypical antipsychotic
Recommend cognitive therapy
Assess adherence and adverse effect burden
In a 2007 study by Blumenthal and colleagues, which of the following interventions was shown to be as effective as SSRI in increasing the probability of remission versus placebo?
* Cognitive therapy
Exercise
Use of a medication reminder app
Behavioral activation
Ideally, most patients diagnosed with MDD should be followed up within ____ of initiating therapy.* 2 to 4 days
1 to 2 weeks
4 to 6 weeks
6 to 8 weeks
In a 2008 study by Cho and colleagues, which of the following was shown to facilitate recurrence of depression?* BMI > 25
BMI > 30
Sleep disturbance
Medication adverse effects

Save and Proceed

Navigating the Road to Recovery in Depression: Pit Stops, Pot Holes, Detours, and Ultimate Recovery: Addressing Barriers to Achieving Recovery in Major Depression

W. Clay Jackson, MD, DipTh, FAAFP

Release Date: January 4, 2018
Expiration Date: January 4, 2019

Continue to Activity

Program Overview

This CME/CNE-certified activity will identify common barriers to achieving recovery in major depression, and evidence-based strategies to overcome those barriers in your patients.

Learning Objectives

Upon completion of this activity, learners should be able to:

Examine common barriers to successful treatment of MDD and evidence-based tools to overcome them

Faculty

W. Clay Jackson, MD, DipTh, FAAFP

Clinical Assistant Professor, Family Medicine and Psychiatry
Fellowship Director for Palliative Medicine
University of Tennessee College of Medicine
Medical Director, Comprehensive Primary Care Medical Director, Methodist Hospice and

Palliative Services
Memphis, TN

Faculty Biography

W. Clay Jackson, MD, DipTh, FAAFP

W. Clay Jackson, MD, DipTh, FAAFP, is a Clinical Assistant Professor of Family Medicine and Psychiatry at the University of Tennessee College of Medicine in Memphis, where he maintains a private practice in family and palliative medicine. He is Medical Director of Comprehensive Primary Care and Medical Director for Methodist Hospice and Palliative Services, also in Memphis. In addition, Dr Jackson is the Fellowship Director for Palliative Medicine at the University of Tennessee College of Medicine. From this professional platform, he has led a team of dedicated clinicians who have helped to transform the experience of seriously ill patients in the Mid-South.

Dr Jackson earned his medical degree at the University of Tennessee Health Science Center in Memphis and completed his residency at the University of Tennessee/Baptist Tipton Family Medicine. He earned his Diploma in Theology at Oxford University in England. He serves as Vice President of the American Academy of Pain Management, is a Fellow of the American Academy of Family Physicians, holds a Certificate of Added Qualification in Hospice and Palliative Medicine, and is a member of the Alpha Omega Alpha Medical Honor Society.

Dr Jackson has been the recipient of many clinical and teaching awards and has had his research published in numerous journals, including Family Medicine, Journal of Affective Disorders, and JAMA. A frequently invited speaker at national and international professional meetings, he has also been featured in several multimedia projects concerning the treatment of affective disorders and chronic pain, as well as the history and philosophy of medicine.

Disclosure Statements

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosures are as follows:

Faculty/Planner

W. Clay Jackson, MD, DipTh, FAAFP
Advisory Board – for scientific information: Sunovion Pharmaceuticals Inc
Officer or Board Member: American Academy of Pain Medicine
Shareholder: Aspire Healthcare
Promotional Speaker’s Bureau: Pamlab, Inc; Sunovion Pharmaceuticals Inc

Planners

Patricia D. Cunningham, DNSc, APRN-BC
Consultant – for educational content/programs: Sunovion Pharmaceuticals Inc; MedEd-Link, Inc; WebMD
Faculty (NP Review Courses): Barkley & Associates, Inc

Rakesh Jain, MD, MPH
Advisory Board – for marketing purposes: Addrenex Pharmaceuticals; Alkermes; Eli Lilly and Company; Forum Pharmaceuticals Inc; Lundbeck; Merck & Co, Inc; Neos Therapeutics, Inc; Otsuka America Pharmaceutical, Inc; Pamlab, Inc; Pfizer Inc; Shionogi Inc; Shire; Sunovion Pharmaceuticals Inc; Takeda Pharmaceuticals U.S.A., Inc
Consultant – for marketing purposes (Self and Spouse/Partner): Addrenex Pharmaceuticals; Eli Lilly and Company; Forest Laboratories; Lundbeck; Merck & Co, Inc; Otsuka America Pharmaceutical, Inc; Pamlab, Inc; Pfizer Inc; Shionogi Inc; Shire; Sunovion Pharmaceuticals, Inc; Takeda Pharmaceuticals U.S.A., Inc
Grant Recipient/Research Support: AstraZeneca; Eli Lilly and Company; Forest Laboratories; Lundbeck; Otsuka America Pharmaceutical, Inc; Pfizer Inc; Shire; Takeda Pharmaceuticals U.S.A., Inc
Promotional Speaker’s Bureau: Addrenex Pharmaceuticals; Alkermes; Eli Lilly and Company; Forest Laboratories; Lundbeck; Merck & Co, Inc; Otsuka America Pharmaceutical, Inc; Pamlab, Inc; Pfizer Inc; Rhodes Pharmaceuticals; Shionogi, Inc; Shire; Sunovion Pharmaceuticals, Inc; Takeda Pharmaceuticals U.S.A., Inc

Sharon Moser, MS, PA-C, LLP
No relevant financial relationships with any commercial interests

American Academy of CME, Inc.

John JD Juchniewicz, MCIS, CHCP, and Natalie Kirkwood, RN, BSN, JD, Lead Nurse Planner
No relevant financial relationships with any commercial interests

Spire Learning

Erika Langsfeld, BSMT, PhD, Christine Kocienda, Kashemi Rorie, PhD
No relevant financial relationships with any commercial interests

Jeanne Prater

Shareholder (spouse/partner): Johnson & Johnson

Employee (spouse/partner): Novo Nordisk

Disclaimer

The opinions expressed in this educational activity are those of the faculty and do not represent those of the Academy, Spire Learning, or American Nurses Credentialing Center’s Commission on Accreditation. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

Off-label Statement

This educational activity does not contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Levels of Evidence

Levels of evidence are provided for any patient care recommendations made during this presentation.

Level A (randomized controlled trial/meta-analysis): High-quality, randomized controlled trial (RCT) that considers all important outcomes. High-quality meta-analysis (quantitative systematic review) using comprehensive search strategies

Level B (other evidence): A well-designed, nonrandomized clinical trial. A nonquantitative systematic review with appropriate search strategies and well-substantiated conclusions. Includes lower-quality RCTs, clinical cohort studies, and case-controlled studies with nonbiased selection of study participants and consistent findings. Other evidence, such as high-quality, historical, uncontrolled studies, or well-designed epidemiologic studies with compelling findings, is also included

Level C (consensus/expert opinion): Consensus viewpoint or expert opinion

Target Audience

Collaborative care team including: Primary Care Physicians, Primary Care Nurse Practitioners and Physician Assistants; Psychiatrists, Psychiatric Nurse Practitioners, and Physician Assistants; Nurses and other team members involved in the care of consumers with MDD

Accreditation

Physicians:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of CME and Spire Learning. The American Academy of CME is accredited by the ACCME to provide continuing medical education for physicians.

The American Academy of CME designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners/Nurses:
The American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

The Academy designates this educational activity for 0.25 contact hours, including 0.1 pharmacotherapeutic contact hours.

Physician Assistants:
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

Method of Participation

There is no fee to participate in the activity, which should take approximately
15 minutes to complete. If you wish to receive CME/CNE credit for participating in this activity, you must view the online activity and complete the online evaluation with a 70% passing score on the posttest. We cannot award credit unless all steps are completed. This credit is valid through December 20, 2018. No credit will be given after this date.

HARDWARE/SOFTWARE REQUIREMENTS:

A computer with an Internet connection

This educational activity is jointly provided by the American Academy of CME, Inc. and Spire Learning.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck

Navigating the Road to Recovery in Depression: Pit Stops, Pot Holes, Detours, and Ultimate Recovery: Addressing Barriers to Achieving Recovery in Major Depression - Pre-Activity Survey

Navigating the Road to Recovery in Depression: Pit Stops, Pot Holes, Detours, and Ultimate Recovery: Addressing Barriers to Achieving Recovery in Major Depression

References for Navigating the Road to Recovery in Depression: Pit Stops, Pot Holes, Detours, and Ultimate Recovery: Addressing Barriers to Achieving Recovery in Major Depression